Overview

Pediatric Open-Label Extension of Voxelotor

Status:
Enrolling by invitation

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

Open-label extension study of voxelotor for pediatric participants ages 4 to 18 years old with Sickle Cell Disease who have participated in voxelotor clinical trials.

Phase:

Phase 3

Details

Lead Sponsor:

Global Blood Therapeutics